Eikon Therapeutics logo

Eikon Therapeutics

Hayward, CA

Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.

https://eikontx.com/

Company Details

Founded

2019

Employees

Between 100 - 500 employees

Raised

$1,122,700,032

Headquarters Location

Hayward, CA

Public

No

Acquired

No

CEO

Roger PerlmutterRoger Perlmutter

Founders

Eric Betzig
Robert Tjian
Robert Tjian
Luke Lavi
Xavier Darzacq
Xavier Darzacq

Company Collections

These are collections Eikon Therapeutics is a part of. Click on the collection name to view similar companies.

Eikon Therapeutics' Industries

Eikon Therapeutics' Tech Stack

Eikon Therapeutics' Investors

Current Job Listings

Listing 0 of 33 job openings

    Eikon Therapeutics Headquarters Location

    3929 Point Eden Way, Hayward, CA 94545

    Total Amount Raised: $1,122,700,032

    Eikon Therapeutics' Investors

    Eikon Therapeutics Funding Rounds

    • Series D

      $350,700,000

      Series D Investors

      Foresite Capital
      Alexandria Venture Investments
      UC Investments
      T. Rowe Price
      StepStone Group
      Lux Capital
      General Catalyst
      The Column Group
      Soros Capital Management
      E15 VC
      AME Cloud Ventures

    • Series C

      $106,000,000

    • Series B

      $518,000,000

      Series B Investors

      UC Investments
      T. Rowe Price
      EcoR1 Capital
      Canada Pension Plan Investment Board (CPPIB)
      Schroders Capital
      Hartford Healthcare Endowment
      Harel Insurance Investments & Financial Services
      StepStone Group
      ADIA (Abu Dhabi Investment Authority)
      Soros Capital Management
      AME Cloud Ventures
      General Catalyst
      E15 VC
      The Column Group
      Innovation Endeavors
      Lux Capital
      Foresite Capital
      Horizons Ventures

    • Series A

      $148,000,000

      Series A Investors

      The Column Group
      Lux Capital
      Innovation Endeavors
      Foresite Capital
      WPSS.bio
      TCG Crossover Management
    Funding info provided by Diffbot.

    Eikon Therapeutics Reviews

    0 out of 5 stars

    Based on 0 reviews

    Review data

    Share your thoughts

    Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Eikon Therapeutics.

    Recent reviews